Guided Therapeutics (OTCMKTS:GTHP – Get Free Report) released its quarterly earnings data on Monday. The company reported ($0.01) earnings per share for the quarter, Zacks reports. The business had revenue of $0.59 million for the quarter.
Guided Therapeutics Price Performance
Shares of GTHP remained flat at $0.23 on Wednesday. 9,496 shares of the company traded hands, compared to its average volume of 16,659. Guided Therapeutics has a 12 month low of $0.06 and a 12 month high of $0.54. The stock has a market cap of $21.27 million, a P/E ratio of -4.60 and a beta of 0.57. The firm has a 50 day simple moving average of $0.34 and a 200 day simple moving average of $0.31.
Guided Therapeutics Company Profile
Guided Therapeutics, Inc is a medical device company focused on the development and commercialization of non‐invasive optical diagnostic platforms for women’s health. Its flagship product, the LuViva® Advanced Cervical Scan, combines hyperspectral and reflectance imaging to support the early detection of cervical epithelial abnormalities. By capturing tissue fluorescence and reflectance signatures in real time, LuViva is designed to augment traditional visual inspection methods and assist clinicians during colposcopic evaluations.
The company secured 510(k) clearance from the U.S.
Read More
Receive News & Ratings for Guided Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guided Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
